DESCRIPTION

JID Innovations is an online-only Open Access journal that provides an international forum for the rapid publication of high-quality, peer reviewed research in the field of skin biology and disease. JID Innovations features original scientific reports related to all aspects of skin science from molecular studies to population health, including studies addressing the pathogenesis and treatment of skin diseases. Submissions should address questions that are important and relevant to the community of researchers and clinicians focused on skin biology and disease. Submissions may confirm or challenge current knowledge, inform the community of a new technology or resource, advance a new hypothesis, or challenge existing paradigms.

JID Innovations invites submission of original scientific articles, clinical trial reports, case reports and case series, descriptions of methods and new technologies, reviews, and letters to the Editor.

The scope of JID Innovations is by design broad. As our subtitle - "Skin science from molecules to population health" - suggests, we will publish articles on all aspects of skin biology and pathology. We are interested in molecular mechanisms and population health. We will be soliciting review articles with a focus on what experiments need to be done, looking forward, not back. We will be interested both in studies that close knowledge gaps and those that expose gaps in our current thinking. We will also seek descriptions of new methods that have great potential in the investigation of skin and skin diseases. We will pursue studies that stimulate and guide future studies; molecular studies that suggest new therapeutic interventions; as well as small clinical trials that provide potentially critical clues for mechanisms of disease.

So-called negative studies that address important questions and are well done are important in formulating future hypotheses, and they are welcome. Clinical trials on small, localized populations help researchers move towards larger definitive trials more quickly; JID Innovations welcomes these submissions as well. Well-done studies that contradict current dogma can open the scientific community’s eyes to new paradigms, and these are also welcome.

JID Innovations is committed to the principle that timely, barrier-free circulation of ideas is the best way to advance understanding.

All submissions to JID Innovations will be subject to rigorous peer review, and all authors will be expected to make their data available for replications through an established data repository or through the authors. Authors who cannot comply with these requirements should not submit their work to JID Innovations.
Queries can be directed to the Editor at InnovationsEditor@sidnet.org.

EDITORIAL BOARD

Editor-in-Chief
Russell P. Hall, Duke University, Durham, North Carolina, United States of America
Autoimmune blistering skin diseases, Pathogenesis, Diagnosis and management of immune mediated primary blistering disorders, Dermatitis herpetiformis, Bullous pemphigoid, Pemphigus vulgaris

Associate Editors
Andrea Chiricozzi, University of Rome Tor Vergata, Roma, Italy
Skin immunology and inflammatory skin disorders, namely psoriasis and atopic dermatitis, Clinical trials, Biologic therapeutics

Thomas Darling, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America
Hameloma syndromes, Mosaicism, and skin regeneration, Tuberous sclerosis complex, Proteus syndrome, Tumor cells, Paracrine factors, Xenograft models, Knockout models, Skin substitutes, Wound healing

Evelyn Gaffal, University Hospital Magdeburg, Magdeburg, Germany
Immunodermatology, Translational research, Pathogenesis of melanoma, Metastatic spread of melanoma, Regulation of cutaneous inflammation

Cristina de Guzman Strong, Washington University in St Louis, Saint Louis, Missouri, United States of America
Itch, Inflammatory skin diseases, Epigenetics, Epidermal development, Population genetics

Heidi Jacobe, UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, Dallas, Texas, United States of America
Clinical research, Translational research, Sclerotic skin conditions, Morphea, Scleroderma

Terry Lechler, Duke University, Durham, North Carolina, United States of America
Epithelial architecture, Cell adhesion, Cytoskeleton

Sung-Jan (Jerry) Lin, National Taiwan University, Taipei, Taiwan
Hair follicles, Regenerative biology, Stem cells, Tissue engineering, Tissue response to radiotherapeutic and Chemotherapeutic injury

Maria Morasso, National Institutes of Health, Bethesda, Maryland, United States of America
Epidermal specification, Development, Ectodermal dysplasias, Transcription, Skin differentiation, Barrier formation, Wound healing

Sang Ho Oh, Yonsei University, Seoul, South Korea
Vitiligo, Autoimmunity, Photomedicine, Pigmentation, Melanogenesis, Melanocyte biology

Ginette Okoye, Howard University Hospital, Washington, District of Columbia, United States of America
Cutaneous disorders of pigmented skin, Scarring alopecia, Hidradenitis suppurativa, Cutaneous T-cell lymphoma, Cutaneous sarcoidosis, Health disparities in dermatology

Michael Rosenblum, University of California San Francisco, San Francisco, California, United States of America
Immunology, Immune response regulation, Transgenic mouse models, Tregs

Enno Schmidt, University of Lubeck, Lubeck, Germany
Inflammatory dermatoses, Autoimmune diseases of skin, Autoimmune blisters and diseases

John T. Seykora, University of Pennsylvania Department of Dermatology, Philadelphia, Pennsylvania, United States of America
Keratinocyte growth and differentiation, Mechanisms of growth control, Squamous cell carcinoma, Signal transduction of tyrosine kinases and adaptor molecules, Murine models

Yayoi Tada, Teikyo University School of Medicine Department of Dermatology, Tokyo, Japan
Langerhans cell biology, Inflammatory skin diseases, Psoriasis, Atopic dermatitis

Jochen Utikal, German Cancer Research Centre, Heidelberg, Germany
Translational skin cancer, Stem cell features of skin cancer cells, Melanoma

Ruth Ann Vleugels, Brigham and Women's Hospital, Boston, Massachusetts, United States of America
Autoimmune skin disease, Autoimmune connective tissue diseases, Emerging medical therapies

Gang Wang, Xijing Hospital, Xian, China
Psoriasis, Autoimmune bullous diseases

Social Media Editor
Mathilda Nicholas, Duke University, Durham, North Carolina, United States of America
Inflammatory diseases of skin, Immunologic diseases of skin, Social media
Statistical Editor

Cynthia Green, Duke University, Durham, North Carolina, United States of America
Biostatistics, Design and analysis of prospective and retrospective studies, Survival analysis, Repeated measures analysis, Causal inference, Predictive modeling
INTRODUCTION

**JID Innovations Scope**

*JID Innovations* is an online-only Open Access journal that provides an international forum for the rapid and open publication of high-quality, peer reviewed research in the field of skin biology and see. *JID Innovations* features original scientific reports related to all aspects of skin science from molecular studies to population health, including studies addressing the pathogenesis and treatment of skin diseases. *JID Innovations* articles should address questions that are important and relevant to the community of researchers and clinicians focused on skin biology and disease. Submissions may confirm or challenge current knowledge, inform the community of a new technology or resource, advance a new hypothesis, or challenge existing paradigms. *JID Innovations* is dedicated to the free dissemination of these reports immediately upon publication, to all scientists and clinicians throughout the world, in order to more quickly advance our understanding of cutaneous biology, skin disease, and treatment.

*JID Innovations* publishes original scientific articles, clinical trial reports, letters to the editor, methods and new technology descriptions, case reports, and reviews.

The scope of *JID Innovations* is by design broad. As our subtitle — “Skin science from molecules to population health” — suggests, we will publish articles on all aspects of skin biology and pathology. We are interested in molecular mechanisms and population health. We will be soliciting review articles with a focus on what experiments need to be done, looking forward, not back. We will be interested both in studies that close knowledge gaps and those that expose gaps in our current thinking. We will also seek descriptions of new methods that have great potential in the investigation of skin and skin diseases. We will pursue studies that stimulate and guide future studies; molecular studies that suggest new therapeutic interventions; as well as small clinical trials that provide potentially critical clues for mechanisms of disease.

So-called negative studies that address important questions and are well done are important in formulating future hypotheses, and they are welcome. Clinical trials on small, localized populations help researchers move towards larger definitive trials more quickly; *JID Innovations* welcomes these submissions as well. Well-done studies that contradict current dogma can open the scientific community's eyes to new paradigms, and these are also welcome. *JID Innovations* is committed to the principle that timely, barrier-free circulation of ideas is the best way to advance understanding.

While *JID Innovations* publishes a wide range of topics related to investigative dermatology, all submissions to *JID Innovations* will be subject to rigorous peer review, and all authors will be expected to make their data available for replications through an established data repository or through the authors. Authors who cannot comply with these requirements should not submit their work to *JID Innovations*.

Queries can be directed to the Editor at InnovationsEditor@sidnet.org.

BEFORE YOU BEGIN

**Ethics in Publishing**

For information on Ethics in publishing and Ethical guidelines for journal publication see https://www.elsevier.com/publishingethics and https://www.elsevier.com/journal-authors/ethics. When addressing issues of publication ethics, *JID Innovations* generally follows the flowcharts published by the Committee on Publication Ethics (COPE; http://www.publicationethics.org).

**Scientific Integrity**

All submissions to and publications in *JID Innovations* are assumed to be the product of honest observations. By submission, the first and senior authors assume full responsibility for the integrity of the work as a whole, from inception to the published article. If substantial doubts arise regarding the scientific integrity of any submission or publication it is the responsibility of the Editor to pursue these issues with the author(s). The first and senior authors assume responsibility for communicating with the editorial office on issues of scientific misconduct or the retraction of a published manuscript, should questions of this type arise. Issues of scientific integrity include but are not limited to duplicate submission and publication, falsification or fabrication of data, and plagiarism. If issues of scientific...
integrity cannot be resolved with the authors to the satisfaction of the Editor, they will be referred to the institution where the work was done and/or the author's funding agency for further investigation. If the work is deemed to be fraudulent, JID Innovations will print a retraction, preferably signed by all authors of the work in question. The editors reserve the right to initiate the retraction of a published manuscript, should it be deemed appropriate. Alternatively, the Editor may choose to print an expression of concern regarding the work, with an explanation.

**Human Studies**

All clinical investigation must have been approved by the author's Institutional Review Board or Research Ethics Committee, and written informed consent must have been obtained from all patients and control participants. All patients referred to in human studies should be identified by number, not by name. Identifying information should not be published in written descriptions, photographs, or pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) has given written informed consent for publication. In addition, retrospective studies must have Institutional Review Board approval. Approvals and patients' and participants' consent should be stated in the Methods section of the manuscript. The editors reserve the right to reject manuscripts that fail to meet these criteria, and to ask for proof of Institutional Review Board approval.

JID Innovations ascribes to NIH's policy on "Consideration of Sex as a Biological Variable in NIH-funded Research." Therefore, as stated in the NIH guidance document, authors should "provide the sex of research subjects and/or materials, when possible. Report when sex differences are, or are not, detected in analyses, as this may be valuable for future research and meta-analysis."

Include a statement affirming that patients consented to publication, if their image or case history is used. For images, this statement should be included at the end of the figure legend.

**Animal Studies**

All animal studies must be approved by the author's Institutional Animal Care and Use Committee and conducted according to the NIH Guide for the Care and Use of Laboratory Animals or equivalent guidelines. This should be stated in the Methods section of the manuscript. The editors reserve the right to reject manuscripts that fail to meet these criteria.

JID Innovations ascribes to NIH's policy on "Consideration of Sex as a Biological Variable in NIH-funded Research." Therefore, as stated in the NIH guidance document, authors should "provide the sex of research subjects and/or materials, when possible. Report when sex differences are, or are not, detected in analyses, as this may be valuable for future research and meta-analysis."

**Conflict of Interest**

Upon submission, each author will receive a unique link to an online form on which they will be asked to declare their qualification for authorship and any conflicts of interest. Each author must indicate on this form whether they have financial, equity, patenting, or other relevant relationships or arrangements with a product or sponsor of research that might constitute a conflict of interest. More information on conflict of interest can be found on the form and in The Uniform Requirements for Manuscripts Submitted to Biomedical Journals, by the International Committee of Medical Journal Editors. Sources of support or declared conflicts should be stated in the manuscript. If the authors have no conflict of interest to declare, this should be noted using the standard phrase, "The authors state no conflict of interest." For more information on Conflict of Interest, see also https://www.elsevier.com/conflictofinterest.

**Submission Declaration**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis; see the 'Prior Publication' section below for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere including electronically in the same form, in English or in any other language, without the written consent of the publisher.

**Prior Publication**

JID Innovations considers results to be published if they have appeared in sufficient detail to allow replication, are publicly accessible with a fixed content, and have been validated by peer review. A summary of work in a review, a perspective, a commentary, a newspaper, or magazine article does
not constitute prior publication, nor does presentation of data in a Master's or Doctoral thesis or the posting of theses in the candidate's institutional repository. Presentation at a national scientific meeting or a webcast of such a meeting, where the data are not published in full, does not constitute prior publication. In cases where data have been presented in an abstract or thesis, this should be stated in the Acknowledgments. Our guiding principle is that journals should interfere minimally in such exchanges.

Preprint postings on a not-for-profit website such as bioRxiv will not constitute prior publication as it relates to eligibility for consideration for publication in *JID Innovations*. Although eligibility for consideration for publication in *JID Innovations* will not be compromised by preprint posting, it is possible that the novelty of any submission could be diminished if widespread publicity is achieved via involvement of media or via other means. Unless required by the authors' funding agency, preprints should be published under a CC-BY-NC-ND license. (For more information about Creative Commons licensing, see [https://creativecommons.org/licenses/by-nc-nd/4.0/](https://creativecommons.org/licenses/by-nc-nd/4.0/)).

**Use of inclusive language**

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns (“clinicians, patients/clients”) as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.

**Authorship Conditions**

*JID Innovations* ascribes to the authorship guidelines described in the *The Uniform Requirements for Manuscripts Submitted to Biomedical Journals*, by the International Committee of Medical Journal Editors. Briefly, each author should have participated sufficiently in the intellectual content of the work to take public responsibility for appropriate portions of its content. Authorship credit should be based on: 1) conception and design, or acquisition of data, or analysis and interpretation of data; 2) drafting or revising the manuscript critically for important intellectual content; 3) final approval of the version to be published; 4) agreement to be accountable for all aspects of the work in ensuring the questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All conditions must be met. In addition, any revisions and the final version of any accepted manuscript must be approved by all authors. Upon submission, each author will receive a unique link to an online form on which they will be asked to declare their qualification for authorship as well as any conflicts of interest.

The contributions of those who do not meet these authorship requirements may be noted in the Acknowledgments section of the manuscript.

**CRediT**

*JID Innovations* uses the CRediT taxonomy to define author contributions. All submissions must include an author contribution list that assigns a defined role to each author and indicates whether the author played a lead, equal, or supporting role related to their contribution. The corresponding author will be charged with the responsibility of providing this list and attesting that all authors have reviewed the list and agree that the role designations are correct. A list of the CRediT contributor roles and definitions is provided below. For more information about CRediT, go to [https://www.casrai.org/credit.html](https://www.casrai.org/credit.html).

**Conceptualization:** Ideas; formulation or evolution of overarching research goals and aims.

**Data Curation:** Management activities to annotate (produce metadata), scrub data and maintain research data (including software code, where it is necessary for interpreting the data itself) for initial use and later reuse.
**Formal Analysis:** Application of statistical, mathematical, computational, or other formal techniques to analyze or synthesize study data.

**Funding Acquisition:** Acquisition of the financial support for the project leading to this publication.

**Investigation:** Conducting a research and investigation process, specifically performing the experiments, or data/evidence collection.

**Methodology:** Development or design of methodology; creation of models.

**Project Administration:** Management and coordination responsibility for the research activity planning and execution.

**Resources:** Provision of study materials, reagents, materials, patients, laboratory samples, animals, instrumentation, computing resources, or other analysis tools.

**Software:** Programming, software development; designing computer programs; implementation of the computer code and supporting algorithms; testing of existing code components.

**Supervision:** Oversight and leadership responsibility for the research activity planning and execution, including mentorship external to the core team.

**Validation:** Verification, whether as a part of the activity or separate, of the overall replication/reproducibility of results/experiments and other research outputs.

**Visualization:** Preparation, creation and/or presentation of the published work, specifically visualization/data presentation.

**Writing - Original Draft Preparation:** Creation and/or presentation of the published work, specifically writing the initial draft (including substantive translation).

**Writing - Review and Editing:** Preparation, creation and/or presentation of the published work by those from the original research group, specifically critical review, commentary or revision - including pre- or post-publication stages.

**ORCiDs**
The unambiguous identification of individuals who are credited as authors and contributors is essential to effective scientific communication. ORCiD identification numbers are required for all authors publishing in *JID Innovations*. For more information regarding ORCiD, and to get your own ORCiD identifier, visit [https://ORCiD.org](https://ORCiD.org).

**Corresponding Author Responsibilities**
Our submission system allows one author to complete the submission process (i.e., submitting author), while designating another to receive correspondence concerning the submission (i.e., corresponding author). Prior to publication, a form asserting Qualification for Authorship and Declaration of Conflict of Interest must be completed by every author. Upon acceptance, the Corresponding Author will be asked to provide the editorial office with the text of the final, accepted manuscript in a Word (.doc) or other document file and one complete set of digital publication-quality figures. Failure to provide these materials will result in a delay in publication. Author proofs and queries will be sent to the Corresponding Author by email; these will require a 48-hour turnaround. No substantive changes may be made in the proof stage without the written approval of the Editor. Journal policy allows ONE corresponding author for published articles. If specific authors are to be addressed concerning particular aspects of the published work, this may be indicated in the Acknowledgments section.

**Changes to Authorship**
Changes in authorship at any point in the review or publication process must be explained to the Editor in a letter signed by all authors, including by any author being added or deleted. The letter must include the original and the revised authorship lists and the reason for the requested change. Approved author changes requested after publication will result in an erratum.
**Authorship Disputes**

Authorship disputes will not be handled by the journal; instead, these will be referred to the authors to resolve. If the authors cannot resolve the issue themselves, the journal will recommend that the authors bring the matter to the attention of their institution(s). Any article with a known authorship dispute will be suspended from review or publication, depending on its status.

**Registering & Reporting Clinical Trials**

*JID Innovations* welcomes submissions of high quality, well-designed clinical trials that have the potential to change clinical practice. *JID Innovations* is particularly interested in clinical research that elucidates disease mechanisms or the mechanisms of action for new therapies. A clinical trial is "any research project that prospectively assigns human subjects to intervention and comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome" (ICMJE definition).

All trials submitted to *JID Innovations* must be 1) prospectively registered and 2) fully reported.

1. **Prospective trial registration.** The purpose of prospective trial registration is to overcome selective reporting bias. *JID Innovations* adheres to the principles set out by the International Committee of Medical Journal Editors (ICMJE) that all clinical trials need to be registered in an approved publicly accessible clinical trial register before patient recruitment begins. A list of ICMJE approved registries can be found [here](#). Studies that register after recruitment has started or after recruitment has been completed will not be considered. The Clinical Trial registration number should be included at the end of the abstract.

2. **Full reporting.** The purpose of complete reporting is to allow our readers to see exactly what was done in the trial so that if needed, the study could be replicated. Many forms of bias can occur within trials, and how these have been dealt with need to be clearly reported. *JID Innovations* endorses the Consolidated Standards of Reporting Trial (CONSORT) Statement and requires authors to report their clinical trials fully according to the latest revision (currently 2010). Authors are required to indicate using this [form](#) where in their manuscript submission the 25 items included in CONSORT 2010 are located, along with a participant [flow diagram](#).

To support full reporting of Clinical Trials, a structured abstract is required.

For details on preparing your RCT for submission, see the [CONSORT website](#).

**Copyright**

Upon acceptance of an article, authors will be asked to complete a 'License Agreement' (see [more information](#) on this). Permitted third party reuse of open access articles is determined by the author's choice of [user license](#).

**Author rights**

As an author you (or your employer or institution) have certain rights to reuse your work. [More information](#).

*Elsevier supports responsible sharing*

Find out how you can [share your research](#) published in Elsevier journals.

**Role of the funding source**

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

**Open Access**

Please visit the Journal's [Open Access page](#).

**Language (Usage and Editing Services)**

Authors may receive criticism from referees or editors about English-language usage in their manuscripts. Grammatical errors may distract readers from your scientific message and may lead to less favorable reviews. To reduce the likelihood of this possibility, we encourage authors who are not native speakers of English to enlist a native English speaking colleague to review their manuscript for
clarity. When this is not possible, authors may wish to use an editing service such as one of those listed below. The use of such services is at the authors' expense and does not guarantee that articles will be accepted. While the services listed below have been vetted, other commercial editing services may be employed instead. *JID Innovations* cannot accept responsibility for the interaction between authors and service providers or for the quality of the work performed.

**Suggested Services:** American Journal Experts, BioScience Writers, DerMEDit, Elsevier's WebShop, Inter-Biotech, SPI Professional Editing Services, and Write Science Right.

**Manuscript Preparation**

Authors are encouraged to read the Journal's Editorial Policies before submitting their work. All submissions must comply with these policies. The journal participates in Elsevier's "Your Paper Your Way" program. Authors may submit manuscripts without strict formatting requirements, provided all the essential elements of an original article are present (i.e. abstract, keywords, introduction, materials and methods, results, conclusions, figures, tables and references). Only upon our acceptance or request for revision will authors be asked to conform to the Journal's publication style. For details about manuscript preparation, see the "Preparation" section below. *JID Innovations* requires electronic submission of manuscripts. For assistance with the site, contact ScholarOne Manuscripts at +1 434-964-4100. For questions regarding your submission, contact the Editorial Office at InnovationsOffice@sidnet.org. You will need the information below to complete your online submission. Submissions are dated according to receipt of all items listed below. No editorial decision will be communicated to the authors until the submission is complete.

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by email.

Please submit your article via [https://mc.manuscriptcentral.com/jidi](https://mc.manuscriptcentral.com/jidi).

**Peer Review**

*JID Innovations* employs ScholarOne Manuscripts to conduct single-blinded peer review (the identity of peer reviewers is kept confidential). Authors may suggest the invitation or exclusion of up to four reviewers at the time of submission. The journal will take these recommendations into consideration; however, the final decision regarding reviewers lies with the Editor. Submissions that will not be fully peer reviewed generally receive a decision within 5 days. Fully peer-reviewed submissions are evaluated by at least two reviewers, one of whom will be a *JID Innovations* Editorial Board member; most will receive a decision within an average of 30 days.

Manuscripts are considered privileged information. Reviewers and editors are instructed to declare any personal or financial conflict of interest on the review forms, and they are expected to maintain confidentiality of a manuscript's contents. Further information about reviewing for *JID Innovations* can be found in our [Reviewer Guidelines](https://www.elsevier.com/locate/xjidi). Final decisions on submitted manuscripts are made by the Editor-in-Chief or a designated editor without relevant conflicts of interest. Editors will recuse themselves from the review of submissions by authors with whom they have relevant personal or research relationships and by authors from their home department and institution.

Editors-in-Chief and members of the Editorial Board are not prevented from submitting manuscripts to their own journals. The Journal strives to ensure that editorial consideration and peer review of such manuscripts is done transparently and rigorously. Editors-in-Chief and Editorial Board members do not participate in the peer-review or decision-making for their own submissions, and they are not allowed access to the details related to the review of their own submissions. A deputy Editor without relevant conflicts of interest will conduct the peer review and make the final decision when manuscripts are submitted by the Editor-in-Chief.

**Revisions**

Revised manuscripts are due within 60 days of receipt of the decision letter. Manuscripts not received within this time will be dated and treated as new submissions. Revisions will be returned to the original reviewers, and new reviewers will be enlisted at the discretion of the Editor. Not all revised manuscripts will be accepted. Any extension must be requested in writing to InnovationsEditor@sidnet.org and
may be granted at the discretion of the Editor. All revised submissions are run through the iThenticate plagiarism checking software. For more information about plagiarism and the use of iThenticate, see the editorial. If, after reconsideration, the manuscript is not suitable for publication with only minor editorial changes, it must be resubmitted as a new manuscript to be reconsidered.

**Submitting a Revision**

**Track Changes.** All changes made in a revised manuscript must be tracked. This will help reviewers locate the changes that correspond with your point-by-point response. Please note in your cover letter if the changes are so extensive (i.e., more than 75% of the document) that it would be unreasonable to underline the changes.

**Responses to Editors and Reviewers.** Responses to reviewers and editors should be included as a text (.doc or .docx) file with the manuscript files and named "Response to Reviewers." When uploading to the submission system, designate the file type as "Cover Letter." Your responses should also be included in the spaces provided in the online system.

**Rebuttals**

Editorial decisions are rarely reversed. Authors with serious concerns about potential scientific errors in the review process may send a rebuttal letter to the editor at InnovationsEditor@sidnet.org. Only written appeals will be considered.

Rejected manuscripts may be resubmitted for consideration only with explicit permission of the Editor and if significant new data are presented. In such cases, the submission will be given a new manuscript number and date of receipt, and it will be treated as a new manuscript.

**Medical Writers**

The journal allows the participation of medical writers in the preparation of manuscripts. The role of the medical writer and the identity of the entity that paid for this assistance should be disclosed in the Acknowledgments section of the manuscript.

**Statistical Guidelines**

The standard error of the mean should be presented only when the intent is to quantify the precision of the sample mean as an estimate of the population mean. The standard deviation should be presented when the intent is to present a descriptive statistic about the sample or an estimate of the population standard deviation. As much as possible, summaries in tables and figures should indicate the sample sizes upon which they are based. For more guidance on statistical methods, refer to the New England Journal of Medicine Instructions to Authors.

**Archiving**

The Editorial Office will retain an electronic file of each manuscript and related correspondence for 12 months following the final editorial decision, or, in the case of accepted manuscripts, publication.

**Announcements**

Brief announcements of scientific meetings, availability of fellowship grants, and awards for research relevant to the readership will be published at the discretion of the Editor. Announcements much reach the editorial office at least 8 weeks before their anticipated publication. In general, announcements will be published only once.

**PREPARATION**

**Fees**

*JID Innovations* does not charge submission fees.

A flat publication fee is imposed. This is $1,500 for SID and ESDR members and $2,000 for non-members.

Investigators from developing countries or with special circumstances are eligible for discounted publication rates, as described by Research4Life or by appeal to the Editor.
General

*JID Innovations* participates in Elsevier's "Your Paper Your Way" program. Authors may submit manuscripts without strict formatting requirements, provided all the essential elements of an original article are present (i.e. abstract, keywords, introduction, materials and methods, results, conclusions, figures, tables and references). Only upon our acceptance or request for revision will authors be asked to conform to the *Journal's* publication style.

Manuscripts should be concise, economical of references, figures and tables, and formatted as described below. Reports of investigative studies should be organized as follows. Details about each section are provided in the instructions that follow. The text may be submitted initially as a .doc, .docx, or .pdf file. Revised manuscripts that do not conform to the specifications below will be returned to the authors for correction.

*How to Format Your Manuscript for Submission to JID Innovations*

**Language:** English (US spelling preferred)

**Font:** 12-point, Times New Roman

**Line Spacing:** Double-spaced throughout

**Margins:** One inch (2.5 cm) on all sides

**Page Numbers:** Use page numbers; start with the title page as page 1. Begin a new page for References, Tables, and Figure Legends.

**Line Numbers:** Do not number lines of text.

**Order of Sections:** Title page, Abstract, Introduction, Results, Discussion (Results and Discussion may be combined into one section), Materials & Methods, Data Availability Statement, ORCiDs, Author Contributions Statement (CRediT-compliant), Acknowledgements, Conflict of Interest, References, Tables, Figure Legends, Supplementary Material.

**Heading Styles:** First level: ALL CAPS, BOLD; Second level: Sentence Case, Bold Underline; Third level: *Sentence Case, Bold Italics*

**Figure Legends:** Provide both a brief, overall title and a detailed legend of 125 words or fewer. The figure title must not refer to individual panels, but describe the overall figure. The legend should describe individual panels in detail.

**File Types:** Text: Word file (.doc or .docx); separate image files (.tif, .jpg, .eps, .pdf, or Microsoft Office) Click here for more info on acceptable figure file formats.

**Article Types**
Below please find requirements for revised articles submitted to *JID Innovations*.

**Original Article:**
Present original research. Investigative studies should be organized as follows: Title page, Abstract, Introduction, Results, Discussion (Results and Discussion may be combined), Materials & Methods (provide full Materials and Methods in this section), Data Availability Statement, ORCiDs, Conflict of Interest Statement, Acknowledgements, Author Contributions Statement (CRediT-compliant), References, Tables, Figure Legends, Supplementary Material (restricted to very large tables, movies, etc. that cannot be typeset; include full Materials and Methods, all figures, and routine sized tables in the main body of the report).

**Letter to the Editor:**
Discussions of published articles. (All reports of original data should be submitted as Original Articles.) Letters should be organized as follows: Title page, Letter, Data Availability Statement, ORCiDs, Conflict of Interest Statement, Acknowledgements, Author Contributions Statement (CRediT-compliant), References, Tables, Figure Legends, Supplementary Material.

**Randomized Clinical Trial:**
Submissions must comply with the CONSORT requirements (http://www.consort-statement.org), including the CONSORT checklist and flow diagram; Word limit: 3,500; Abstract word limit: 200 (a structured abstract is required. See the CONSORT guidelines for details at http://www.consort-statement.org/checklists/view/32-consort/67-abstract).

**Case Reports/Case Series:**
Case reports and series which describe 3 or more patients will be considered for *JID Innovations*. These reports should provide new and important observations related to at least one of the following areas of investigation: clinical presentation, clinical responses to therapy, mechanisms of therapy, pathogenesis of the disease, or new adverse events associated with treatments including new drug reactions.

Case Reports should be organized as follows: Abstract, Introduction, Case Report, Discussion, Data Availability Statement, ORCiDs, Conflict of Interest, Acknowledgments, Author Contributions Statement (CRediT-compliant), References, Tables, Figure Legends, Supplementary Material (restricted to very large tables, movies, etc. that cannot be typeset; include full Materials and Methods, all figures, and routine sized tables in the main body of the report).

**Methods and New Technology:**
Submissions detailing new methods and new technology will be considered for *JID Innovations*. These submissions should describe new methods or new technological advances which heretofore have not been widely utilized in the investigation of skin biology or dermatologic diseases. These reports must completely describe both the theory and the practical application of the technology, examples of its utility in other areas of science, and its potential utility in the study of skin biology or dermatologic diseases. Examples of the application of the method or technology in skin biology or dermatologic research is preferred but not required.

Methods and New Technology submissions should be organized as follows: Abstract, Introduction, Methods & Description, Results, Discussion and Potential Applications, Data Availability Statement, ORCiDs, Conflict of Interest, Acknowledgments, Author Contributions Statement (CRediT-compliant), References, Tables, Figure Legends, Supplementary Material (restricted to very large tables, movies, etc. that cannot be typeset; include full Materials and Methods, all figures, and routine sized tables in the main body of the report).

**Review Article:**
Comprehensive, scholarly, and balanced, presenting an expert curation of the literature in the topic of interest. Consult the Editor at InnovationsEditor@sidnet.org before submission. Include an abstract or outline, the proposed author list with institutions, and a list of the authors' relevant publications to support your proposal. Submission guidelines will be provided to authors whose proposals are accepted.

**Cover Letter**

**Meeting Report:**
Meeting Reports are scientific publications geared to informing the cutaneous biology community of important new observations that may be relevant to cutting edge research. Consult the Editor at InnovationsEditor@sidnet.org before submission. Submission guidelines will be provided to authors whose proposals are accepted.

**Cover Letter**
The cover letter must summarize the research being reported and describe its importance and relevance to the *JID Innovations* audience.

**Submissions Checklist**
Submissions must include:
One-page cover letter. Authorship Qualification & Declaration of Conflict of Interest form, signed by all authors. (This form will be presented within the submission system, and an email will be sent to all authors requesting they complete it.) Text file (.doc or .docx). Figure files (.tif, .eps, or .ppt), if the submission includes figures. Note: Figures may be embedded in initial submissions for review purposes. You will be asked to enter an email address for every author; have this information ready. Graphical Abstract (for Original Articles, if desired).ORCiDs for all authors. For more information about ORCiD, see https://orcid.org/ and the related Editorial [https://www.jidonline.org/article/S0022-202X(18)31983-3/fulltext].
each author's contribution to the submitted work using the CRediT taxonomy. For more information about CRediT, see https://www.casrai.org/credit.html and the related editorial [https://www.jidonline.org/article/S0022-202X(18)31983-3/fulltext].

**Title Page**
The title page should include the following:
Brief, informative title of 120 characters or fewer (brand names may not be used in the title) Authors’ full names, ORCIDs (for more information, see https://orcid.org/), departments, and institutions (indicate affiliations numerically with numbers placed after authors’ names and before the institutions); All authors’ emails are required by our electronic submission system. Have these ready at the time of submission; City, state and country in which the work was done; Corresponding author’s address, telephone, and email (email address required); Short title of 45 characters or fewer, including spaces; Abbreviations used (see below for detail on abbreviations)

**Abstract**
Do not exceed 200 words; Briefly summarize the background, purpose, results and conclusions of the study, in that order, without headings; Do not include nonstandard abbreviations, acknowledgments of support, or refer to footnotes or references; Write with a general scientific audience in mind; Brand names may not be used in the abstract; For Letters to the Editor, enter a brief summary of the major findings space provided in the submission system; otherwise, an Abstract is not required for Letters to the Editor; For Randomized Clinical Trials, a structured abstract is required. For details, refer to the CONSORT guidelines for abstracts.

**Introduction**
Begin with a brief introductory statement that places the work to follow in historical perspective and explains its intent and significance.

**Results and Discussion**
In the Results section, briefly present the experimental data in text, tables, or figures. The Discussion should focus on the interpretation and significance of the findings with concise, objective comments that describe their relation to other work in the area. Do not repeat information from the Results. Results and Discussion may be presented separately or combined into a single section.

**Materials and Methods**
Readers should be able to fully understand and reproduce the experiments described from the information in the Materials and Methods section, Figure Legends, Table footnotes, and References, in conjunction with the Supplementary Material. The manufacturer's name and location (city, state if within the US; city, country if outside the US) should be provided for materials that were purchased. This would normally include the identity (chemical formula) of all reagents employed. Unique non-proprietary reagents that are utilized (e.g., cells, DNA, antibodies) and instruments created for surveys of accepted articles must be made freely available to qualified scientists. Only under this condition is the information useful to the scientific community, and only in this way can results be reproduced by other scientists.

Manuscripts reporting human studies must include a statement that all human studies were approved by the authors' Institutional Review Board and affirming that patients gave their written, informed consent. Reports of Clinical Trials must conform to the Editorial Policies concerning the registration and reporting of Clinical Trials. Submissions that do not comply with these specifications will be returned to the authors for correction prior to review.

Manuscripts reporting animal studies must include a statement that the authors’ institution approved the studies and that they were conducted according to the NIH Guide for the Care and Use of Laboratory Animals or equivalent guidelines.

**Data Availability Statement**
*JID Innovations* seeks to enable researchers and facilitate research progress. To that end, primary research data should be made available free of charge to all researchers wherever possible and with minimal reuse restrictions. All *JID Innovations* submissions must include a "Data Availability Statement" section that follows the Materials & Methods section of the manuscript. Authors should describe the availability of the minimal dataset that would be necessary to interpret, replicate and build upon the current submission. It is expected that large datasets (such as, but not limited to, gene expression arrays, SNP arrays, proteomic datasets, high throughput sequencing and GWAS data) will be deposited in recognized public repositories (such as, but not limited to, GenBank and EMBL)
for DNA and RNA sequences, Protein Databank for molecular models, GEO and Array Express for MIAME-compliant microarray data, etc.), and that datasets will be accessible at the time of online publication. Authors should choose the most appropriate data repository based on data type and standard practices of the field. If no specific database exists, we encourage authors to deposit data in an appropriate publicly available repository, such as Mendeley. For clinical trial submissions, the Data Availability Statement should comply with the ICMJE Data Sharing requirement: indicate what data will be shared, to whom it will be accessible, and when, how, and where that data will be made available; an accession number should also be included. If data cannot be shared for legal or ethical reasons or if there are embargoes on datasets, authors must inform the editors at the time of submission and explain the restrictions on the dataset or materials. Restrictions on data accessibility may prevent publication of related submissions. Failure to comply with this policy will trigger retraction of the manuscript from consideration by the Journal.

The "Data Availability Statement" should be presented as follows: "Datasets related to this article can be found at [URL/s linked to dataset/s], hosted at [Name of repository] (Citation to dataset)."

If no datasets were generated or analyzed, the authors should state "No datasets were generated or analyzed during the current study."

Example:

Datasets related to this article can be found at http://dx.doi.org/10.17632/fhvsfjx7j6.1, an open-source online data repository hosted at Mendeley Data (Chen and Maloof, 2017).

It is also essential that researchers be credited for sharing their research data. Therefore, authors must appropriately acknowledge datasets they access as they perform their work. Citations of such data sets should be presented in the "References" section, and they should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so it can properly be identified as a data reference. The [dataset] identifier will not appear in published articles.

Example:


ORCIDs for All Authors

The unambiguous identification of individuals who are credited as authors and contributors is essential to effective scientific communication. ORCID identification numbers are required for all authors publishing in JID Innovations. For more information regarding ORCID, and to get your own ORCID identifier, visit https://ORCID.org.

Conflict of Interest Statement

Financial or personal involvements that pose a potential duality of interest for authors should be clearly disclosed in the manuscript under the heading "Conflict of Interest." If no conflicts exist, please use the standard phrase, "The authors state no conflict of interest." Upon submission, all authors will be asked to declare any conflicts of interest on an Authorship Disclosure Form.

Acknowledgments

A note of acknowledgment is appropriate recognition for contributors who provided help during the research but whose contributions do not qualify them as authors. For details on authorship, see the Authorship section.

Author Contributions Statement

JID Innovations uses the CRediT taxonomy to define author contributions. All submissions must include an author contribution list that assigns a defined role to each author and indicates whether the author played a lead, equal, or supporting role related to their contribution. The corresponding author will be charged with the responsibility of providing this list and attesting that all authors have reviewed the list and agree that the role designations are correct. For more information about CRediT, see the CRediT section above, or go to https://www.casrai.org/credit.html.
References
The journal's EndNote page can be found here: https://endnote.com/style_download/journal-of-investigative-dermatology/.

Details about the JID Innovations reference style can be found here.

References should be listed alphabetically on a separate page at the end of the manuscript. List the first 6 authors, followed by et al if there are more. If necessary, further sort the list chronologically. More than one reference from the same author(s) in the same year must be identified by the letters "a," "b," "c," etc. placed after the year of publication. To save space, the citation of appropriate recent review articles is encouraged. Only published articles, published abstracts, and manuscripts in press should be cited in the references. Any references listed as "in press" should be submitted with the manuscript for the reviewers' reference. For details, see the table below:

Footnotes
Any citations to unpublished works or preprints must be shown as footnotes, not in the reference list. Footnotes should be presented in parentheses in the text.

Tables
Create tables in an editable format. Include them in your text file. Tables should be self-explanatory and not duplicate content from the text. Present one table per page. Number tables sequentially (1, 2, 3) and cite them in chronological order in the text. Each table should include an informative title. Provide the description of the experiment, definition of columns or abbreviations, etc. in footnotes to the title and table contents. Label footnotes 1, 2, 3, etc. Define errors in the table by a footnote, e.g., "mean +/- SD" or "mean +/-SEM". Check that the data in the tables are consistent with those cited in the relevant papers in the text, totals add up correctly, and percentages have been calculated correctly. If possible, limit each table to a maximum of one page. (The editor reserves the right to move large tables to supplementary material.)

Figures
Figures should be intelligible without reference to the text and should complement the text. Figures should be labeled sequentially (1, 2, 3) and cited in the text, but not embedded within the text. Figures should be submitted as individual image (.eps, .tif, .ppt) files, not as .pdfs.

Artwork Guidelines
Detailed guidelines for submitting artwork for publication can be found in the artwork instructions. Submit production quality artwork with your initial submission. Please note: file size limitations may require that publication-quality figures be compressed for submission and peer review purposes.

Appropriate Conduct Concerning Images
No specific feature within an image may be enhanced, obscured, moved, removed, or introduced. Adjustments of brightness, contrast, or color balance are acceptable if they are applied to the whole image, and as long as they do not obscure or eliminate any information present in the original. The grouping of images from different parts of the same gel, or from different gels, fields, or exposures must be made explicit by arrangement of the figure (i.e., using dividing lines) and in the text of the figure legend. If the original data cannot be supplied by the author upon request, the acceptance of the manuscript may be revoked. Refer to the article "What's in a picture? The temptation of image manipulation" by Rossner and Yamada (J Cell Biol 166:11-15, 2004) for details.

Figure Titles & Legends
Present the figure title (a brief, overall description of the figure) in the legend that is included in the text. Do not put the title on the figure. Legends should explain how an experiment was done and identify parts of the figure (i.e., a, b, c); they should not interpret the figure. Indicate the meaning of all symbols, keys and abbreviations used in the figure. Error bars should be defined in the legend as "mean +/- SD" or "mean+/-SEM." If you use SEM give n for each point.

Figure Sizing
Figures must be supplied at a minimum resolution of 300 dpi. Submit artwork of exact column measurements and crop out unnecessary areas (1 column = 87.50mm; 2 columns = 180mm). Most figures should be presented at 1 column width (or quarter page in size). Illustrative elements (figure/tables) are limited to \( \frac{1}{4} \) page each (approx 87.5 mm x 115 mm). Authors may supply fewer, larger
elements (i.e., for an original article three ½-page figures may be presented rather than six ¼-page figures — or any combination that results in no more than 1 ½ pages of figures and tables). In addition, 500 words of text may be substituted for one figure, or vice versa.

**Figure Labeling**
Figure parts should be noted as a, b, c, etc., in lower case Arial font. Place labels in the white space above or beside the image. Use uniform lettering and sizing to ensure that labels are legible if figures must be re-sized.

**Line Drawings**
Line drawings should be supplied at 600 dpi. Drawings should have clear, uniform lines of thickness. Curves should be smooth. Use 3-dimensional graphs only to present a third dimension of data. Label axes parallel to the axis. Labels must be clearly legible. Color may be used in charts and graphs. If using black and white, bar graphs should use a patterned print (not shades of gray).

**Photomicrographs**
A scale bar (not magnification) must be placed on micrographs. Indicate the scale in the legend only, e.g., "scale bar = mm". Place labels in the white space above or beside the image.

**Figure Formats**
For help with electronic artwork, go to [https://www.elsevier.com/artworkinstructions](https://www.elsevier.com/artworkinstructions). Some highlights are provided below. Artwork created in a Microsoft Office application (Word, PowerPoint, Excel) should be supplied "as-is" in its native document format. For all other applications, "save as" or convert images to one of the following formats (note resolution requirements):EPS (or PDF): Vector drawings, embed all used fonts TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi TIFF (or JPEG): Bitmapped (pure black & white pixels), line drawings, keep to a minimum of 1000 dpi TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi **DO NOT** Optimize for screen use (e.g., GIF, BMP, PICT, WPG); these have a low number of pixels and a limited set of colors. Embed the used fonts if the application provides that option.

**Permissions**
If you include previously published or copyrighted material in your manuscript, obtain written permission from the copyright owner to reproduce the material in both print and electronic formats and submit this authorization with the manuscript. This applies to quotes, illustrations, and other materials taken from previously published works not in the public domain. The original source should be cited (if reprinting a figure or table, the citation should appear in the figure legend or table footnote).

**Abbreviations**
Define abbreviations that are not standard in this field in a footnote placed on the title page. Ensure consistency of abbreviations throughout the article. Terms used more than five times may be abbreviated and listed with their abbreviations on the title page. Abbreviations not listed in the Standard or Recommended Abbreviations should conform to those listed in Scientific Style & Format, 8th ed. (University of Chicago Press, Chicago, IL USA, 2014). Capitalize trade names, but use generic names if possible. Trade names may not be used in the title or abstract. The trivial names of chemicals may be used if the formal chemical name is given with the first use of the trivial name.

**Reporting on Cell Line Use**
**JID Innovations** ascribes to the guidelines provided by the American Association for Cancer Research (AACR; [http://www.aacrjournals.org/site/AuthServCtr/cell_line_auth.xhtml](http://www.aacrjournals.org/site/AuthServCtr/cell_line_auth.xhtml)), which state that if cell lines were used in research, a statement addressing the following points must be included in the Materials & Methods section of the manuscript: From where and when the cells were obtained Whether the cell lines have been tested and authenticated The method by which the cells were tested for mycobacterial or other contamination and for DNA mutations How and when the cells were last tested If cells were obtained directly from a cell bank that performs cell line characterizations and passaged in the user's laboratory for fewer than 6 months after receipt or resuscitation, re-authentication is not required. In these cases, the author should include the method of characterization used by the cell bank.

**Provide the Sex of Research Subjects/Animals**
**JID Innovations** ascribes to NIH's policy on "Consideration of Sex as a Biological Variable in NIH-funded Research." Therefore, as stated in the [NIH guidance document](https://www.nih.gov), authors should "provide the sex of research subjects and/or materials, when possible. Report when sex differences are, or are not, detected in analyses, as this may be valuable for future research and meta-analysis.”
**Supplementary Material**

*JID Innovations* accepts electronic supplementary material to support and enhance scientific publication. Supplementary files offer the author opportunities to publish supporting applications, high-resolution images, background datasets, sound clips, and more. Supplementary files will be published online alongside the electronic version of articles. The print version must be complete and self-explanatory without the supplementary information. Supplemental Material must be supplied to the editorial office in its final form for peer review. Supplementary material should be cited in the text as "Movie S1, S2, etc." Please use one of the recommended file formats described below. Supply a concise and descriptive caption for each file.

Supplementary materials that cannot be typeset (i.e., videos, audio files, spreadsheets) should be supplied as individual files as well and will publish online with your article in the format they were received.

**AFTER ACCEPTANCE**

**Embargo Policy**

All articles accepted for publication in *JID Innovations* are embargoed until the date of online publication.

For Original Articles and Letters to the Editor, both of which are published online before copyediting and typesetting, the following guidelines apply. The publication of the accepted manuscript online is an official publication of a *JID Innovations* article. It is a .pdf of the accepted version of an article, before copyediting, typesetting, or proofing. Original Articles and Letters to the Editor are only embargoed until the accepted manuscript version is published online. In general, this will be 2-4 business days following export of the accepted article to the publisher, although this may vary.

Reviews and Editorial material (commentaries, editorials, etc) are embargoed until the date of online publication of the copyedited, typeset, and proofed version of the article.

**Availability of Accepted Article**

*JID Innovations* makes Original Articles and Letters to the Editor available online as soon as possible after acceptance by publishing the accepted article (both in HTML and PDF format), which has not yet been copyedited, typeset or proofread. A Digital Object Identifier (DOI) is assigned, thereby making the articles fully citable and searchable by title, author name(s) and the full text. The article carries a disclaimer stating that it is an unedited article. Subsequent production stages will replace this version. The same DOI will be used for all versions.

**Use of the Digital Object Identifier**

The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. Example of a correctly given DOI (in URL format): http://dx.doi.org/10.1038/JID.2015.386.

When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to change.

**Online proof correction**

To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this
stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

**Offprints**
Corresponding and co-authors may order offprints at any time via Elsevier's WebShop.

**Publication Charges**
A flat publication fee is imposed. This is $1,500 for SID and ESDR members and $2,000 for non-members.

Investigators from developing countries or with special circumstances are eligible for discounted publication rates, as described by Research4Life or by appeal to the Editor.

**Author Inquiries**
You can track your submitted article at https://mc.manuscriptcentral.com/jidi. You can track your accepted article at https://www.elsevier.com/trackarticle. Or, contact the Editorial Office at InnovationsOffice@sidnet.org (Phone: 919-932-0140). You are also welcome to contact Customer Support via https://service.elsevier.com.

**Instructions for Authors - PDF Download**
Click here to download a PDF of the *JID Innovations* Instructions for Authors.

**Optional Graphical Abstract**
A graphical abstract is optional for Original Articles, but its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 31 x 1328 pixels (h x w) or proportionally more. The image should be readable at a size of 5 x 13 cm using a regular screen resolution fo 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view Example Graphical Abstracts here on our information site.

Name the file "Graphical_Abstract". The Graphical Abstract can be a figure that also appears in the article. In this case, authors should upload the figure twice: once as the graphical abstract and once as the manuscript figure.

Authors can make use of Elsevier's Illustration Services to ensure the best presentation of their images in accordance with all technical requirements. An estimate of cost will be provided within 24 hours.

© Copyright 2018 Elsevier | https://www.elsevier.com